Evidence map›Paper›PMID 32908987›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.

Eshan U Patel, Evan M Bloch, William Clarke, Yu-Hsiang Hsieh, Denali Boon, Yolanda Eby, Reinaldo E Fernandez, Owen R Baker, Morgan Keruly, Charles S Kirby and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 44 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 1 country.

Eshan U PatelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yu-Hsiang HsiehDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Denali BoonDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Yolanda EbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Reinaldo E FernandezDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Owen R BakerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
Morgan KerulyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Charles S KirbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ethan KlockDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kirsten LittlefieldDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jernelle MillerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Haley A SchmidtDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Philip SullivanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Estelle Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ruchee ShresthaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew D ReddDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard E RothmanDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David SullivanDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Shmuel ShohamDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Thomas C QuinnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oliver LaeyendeckerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USNational Institutes of Health · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
NIDA Epidemiology Training Program: Johns Hopkins UniversityT32DA007292 · NIDA · JOHNS HOPKINS UNIVERSITY · PI RENEE M. JOHNSON, Brion S Maher · 1993 to 2026
$17.7M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
A prospective evaluation of chronic B.microti infection in seroreactive blood donR21HL117140 · NHLBI · VITALANT · PI BLOCH, EVAN MARTIN · 2013 to 2014
$452k
NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS HHSN272201400007CNIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI152078NIAID NIH HHS T32 AI102623NIAID NIH HHS UM1 AI068613NIDA NIH HHS T32 DA007292
6 · The paper itself

Abstract

Accurate serological assays to detect antibodies to SARS-CoV-2 are needed to characterize the epidemiology of SARS-CoV-2 infection and identify potential candidates for COVID-19 convalescent plasma (CCP) donation. This study compared the performance of commercial enzyme immunoassays (EIAs) to detect IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAb). The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) to detect IgG or total antibodies to SARS-CoV-2 was evaluated from cross-sectional samples of potential CCP donors that had prior molecular confirmation of SARS-CoV-2 infection for sensitivity (n=214) and pre-pandemic emergency department patients for specificity (n=1,102). Of the 214 potential CCP donors, all were sampled >14 days since symptom onset and only a minority had been hospitalized due to COVID-19 (n=16 [7.5%]); 140 potential CCP donors were tested by all five EIAs and a microneutralization assay. When performed according to the manufacturers' protocol to detect IgG or total antibodies to SARS-CoV-2, the sensitivity of each EIA ranged from 76.4% to 93.9%, and the specificity of each EIA ranged from 87.0% to 99.6%. Using a nAb titer cutoff of ≥160 as the reference positive test (n=140 CCP donors), the empirical area under receiver operating curve of each EIA ranged from 0.66 (Roche) to 0.90 (Euroimmun). Commercial EIAs with high diagnostic accuracy to detect SARS-CoV-2 antibodies did not necessarily have high diagnostic accuracy to detect high nAbs. Some but not all commercial EIAs may be useful in the identification of individuals with high nAbs in convalescent individuals.

Identifiers

PMID32908987
PMCPMC7480035
OpenAlexW3081942847

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.